Vaccine Elicits Immune Responses in Pancreatic Most cancers

In an announcement, the off-the-shelf vaccine ELI-002 7P elicited sturdy mKRAS-specific T-cell responses in 89 out of 90, or roughly 99%, of evaluable sufferers with pancreatic most cancers.

The information had been introduced in a information launch issued by Elicio Therapeutics, a clinical-stage biotechnology firm that developed the most cancers vaccine.

“We’re extraordinarily inspired by the T-cell immunogenicity knowledge from the continued section 2 ELI-002 7P trial,” commented Robert Connelly, Chief Government Officer of Elicio, within the information launch. “The strong T-cell responses noticed are extremely per our constructive section 1 outcomes and additional improve our confidence within the ongoing section 2 trial, as T-cell immune responses in section 1 trials for ELI-002 2P and ELI-002 7P had been considerably correlated with scientific exercise in minimal residual disease-positive sufferers. These vital knowledge set the stage for the ultimate disease-free survival evaluation within the AMPLIFY-7P trial, which is anticipated to happen within the fourth quarter of 2025.”

The section 2 AMPLIFY-7P scientific trial included each minimal residual disease-positive and -negative sufferers, which means those that did and didn’t have very small hint quantities of most cancers remaining that had been detectable by a blood check.

How Does ELI-002 Work?

In line with the information launch, ELI-002 targets cancers pushed by mutations within the KRAS gene, which is a driver of many human cancers. The ELI-002 7P iteration of the vaccine is meant to supply an immune response towards seven of the commonest KRAS mutations present in 1 / 4 of all strong tumors. As beforehand reported by CURE, the primary affected person was dosed within the AMPLIFY-7P trial in January 2024.

“This vaccine works like most vaccines hopefully work, which is to have interaction and stimulate an immune response towards a most cancers protein, and that features T-cells and B-cells and all of your immune cells to acknowledge most cancers cells as international and to have interaction within the struggle towards them,” defined Dr. Zev Wainberg in an interview with CURE. Wainberg is the primary creator of a examine on ELI-002 2P, one other iteration of the vaccine, which was revealed in Nature Medication.

Wainberg can be a professor of medication on the David Geffen Faculty of Medication at UCLA and a researcher within the UCLA Well being Jonsson Complete Most cancers Middle.

Dr. Wainberg mentioned the importance of the vaccine’s “off-the-shelf” standing for sufferers. “It means it is a vaccine that may be readily and simply accessible as a result of it does not need to be personalised,” he stated. “Customized signifies that it’s important to ship the tumor in and do a whole lot of manipulation to create the vaccine. As a result of the goal of curiosity on this vaccine was a KRAS, which is so ubiquitous amongst, for instance, 90% of pancreas most cancers and 50% of colon most cancers, due to the excessive frequency of that, it is a good candidate for an off-the-shelf vaccine.”

Moreover, he defined how this vaccine, if it makes it to market, will deal with unmet wants for sufferers. “One of many challenges that is fairly distinctive in pancreatic most cancers is that even after the affected person will get an operation and will get chemo and radiation, no matter else they’ll do, they nonetheless have a really, very excessive threat of recurrence, and that’s fairly distinctive, I’d say,” he defined. “It is the very best threat of recurrence after a most cancers has been eliminated in comparison with any others—breast, colon, lung, you identify it. Due to that top threat, they’re all the time, sadly, going to need to take care of it once more, and typically in a deadly approach.”

For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.

Reference

1. “Elicio Therapeutics Stories ELI-002 7P Achieved Sturdy mKRAS-Particular T Cell Responses in 99% of Evaluable Sufferers in Ongoing Part 2 AMPLIFY-7P Trial,” by Elicio Therapeutics. Information launch; Sept. 17, 2025.
2. “First Affected person Dosed in Part 2 Most cancers Vaccine Trial,” by Alex Biese. CURE; Feb. 1, 2024. https://www.curetoday.com/view/first-patient-dosed-in-phase-2-cancer-vaccine-trial
3. “Off-The-Shelf Vaccine Elicits Sturdy Responses in Pancreatic, Colorectal Cancers,” by Alex Biese. CURE; Aug. 13, 2025. https://www.curetoday.com/view/off-the-shelf-vaccine-elicits-durable-responses-in-pancreatic-colorectal-cancers